Myovant Sciences
2000 Sierra Point Parkway, Suite 900
Brisbane, CA 94005
United States
Tel: 650-392-0222
Website: https://www.myovant.com/
About Myovant Sciences
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
122 articles with Myovant Sciences
-
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
11/23/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021.
-
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
11/8/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Nancy Valente, M.D. as an independent member of the company’s Board of Directors.
-
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
10/26/2021
Myovant SciencesMyovant Sciences, a healthcare company focused on redefining care for women and for men, announced financial results for the second quarter of fiscal year 2021 and other corporate updates.
-
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
10/19/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in premenopausal women with uterine fibroids and in women with endometriosis pain (an investigational use).
-
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
10/12/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021.
-
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
9/9/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.
-
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
9/1/2021
Myovant Sciences will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time
-
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
8/12/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.
-
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
7/28/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced corporate updates and financial results for the first quarter of fiscal year 2021.
-
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
7/20/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the European Commission has approved the marketing authorization application for RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use.
-
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
7/14/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter 2021, ended June 30, 2021.
-
Myovant Sciences to Present at Upcoming Investor Conferences - June 01, 2021
6/1/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences
-
The U.S. FDA is starting off the summer months with a busy week after the Memorial Day holiday in the U.S. Here’s a look.
-
The U.S. FDA has granted approval to MYFEMBREE, Myovant Sciences, and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
-
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
5/21/2021
CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FDA review with a target action date of June 1, 2021
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
5/11/2021
Company remains well-capitalized with cash, cash equivalents, marketable securities and committed funding of $726.2 million as of March 31, 2021
-
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
5/4/2021
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its fourth fiscal quarter and fiscal year 2020, ended March 31, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on May 11, 2021.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
4/12/2021
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)
-
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
4/5/2021
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021.